Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

PaperCitations, authors & open-access status

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,157 citations, 2017 year and closed oa status.

1,157
Citations
2017
Year
closed
OA Status

Related on ScholarIQ

Denis Moro‐Sibilot
Author
Daniel S.W. Tan
Author
Chong‐Jen Yu
Author
Yi‐Long Wu
Author
The Lancet
Journal
Lung Cancer Treatments and Mutations
Topic
470M+ articles · free account